Plain-English translation of NCT06941857 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a new medication, combined with chemotherapy (FOLFIRINOX) and an immune-boosting drug called —with or without a second immune drug called . The study wants to see if this combination is safe and tolerable for patients with metastatic pancreatic cancer (cancer that has spread beyond the pancreas) who have never received chemotherapy before.
Pancreatic cancer that has spread is very difficult to treat and has poor outcomes with current standard treatments. This trial is exploring whether adding this new medication to existing chemotherapy and immune therapy might help patients live longer and with fewer severe side effects.
You likely qualify if…
You likely don't qualify if…
You would receive the new medication combination either as an outpatient or inpatient, depending on the treatment plan. The study involves regular doctor visits for blood tests, imaging scans, and physical exams to monitor how well the treatment is working and check for side effects. Your doctors will be watching closely for safety and may adjust your treatment based on how your body responds. The trial is small (enrolling about 20 patients total) and is focused on understanding if this combination is safe before larger studies are done.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States